Callan Family Office LLC Acquires 21,742 Shares of Eli Lilly and Company (NYSE:LLY)

Callan Family Office LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 2,849.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 22,505 shares of the company’s stock after purchasing an additional 21,742 shares during the quarter. Eli Lilly and Company comprises 1.1% of Callan Family Office LLC’s holdings, making the stock its 15th largest holding. Callan Family Office LLC’s holdings in Eli Lilly and Company were worth $17,374,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Hartford Funds Management Co LLC increased its stake in shares of Eli Lilly and Company by 3.1% in the 4th quarter. Hartford Funds Management Co LLC now owns 1,462 shares of the company’s stock valued at $1,129,000 after acquiring an additional 44 shares in the last quarter. Chatham Capital Group Inc. grew its holdings in Eli Lilly and Company by 1.3% in the fourth quarter. Chatham Capital Group Inc. now owns 9,424 shares of the company’s stock worth $7,275,000 after purchasing an additional 124 shares during the period. Welch & Forbes LLC grew its holdings in Eli Lilly and Company by 9.0% in the fourth quarter. Welch & Forbes LLC now owns 146,980 shares of the company’s stock worth $113,469,000 after purchasing an additional 12,088 shares during the period. E Fund Management Co. Ltd. raised its holdings in shares of Eli Lilly and Company by 66.7% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,270 shares of the company’s stock valued at $7,156,000 after purchasing an additional 3,708 shares during the period. Finally, Candriam S.C.A. boosted its position in shares of Eli Lilly and Company by 3.6% during the 4th quarter. Candriam S.C.A. now owns 524,212 shares of the company’s stock worth $404,692,000 after purchasing an additional 18,313 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 1.8 %

NYSE LLY opened at $912.73 on Friday. The business’s fifty day moving average is $824.92 and its 200-day moving average is $849.05. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock has a market capitalization of $865.43 billion, a price-to-earnings ratio of 77.94, a PEG ratio of 1.40 and a beta of 0.42. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its board has authorized a stock repurchase program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio is currently 51.24%.

Wall Street Analyst Weigh In

A number of analysts recently commented on LLY shares. Wolfe Research started coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price for the company. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a report on Friday, January 17th. Bank of America reaffirmed a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Finally, StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,007.50.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.